PETALING JAYA: Healthcare and pharmaceutical company Hovid Bhd has received a manufacturing licence for its Ipoh plant.
The licence, given yesterday, enables the company to resume its operations.
It is valid from May 5 and is to be renewed three months prior to the expiry date on Dec 31, 2017.
Issued by the National Pharmaceutical Control Bureau under the Ministry of Health Malaysia, the licence is for Hovid’s Ipoh manufacturing plant located along Jalan Tunku Abdul Rahman.
In January, the Health Ministry had repealed the manufacturing licences of both of Hovid’s facilities in Perak.
The revocation order came following an audit by the National Pharmaceutical Regulatory Agency (NPRA) on Hovid’s facilities, which found that the latter’s Good Manufacturing Practice (GMP) compliance was not acceptable and its pharmaceutical quality system did not comply with the latest GMP requirements.
The re-issuance of the licences would be subject to the NPRA being satisfied with the outcome of its audit.
In March, Hovid had received the manufacturing licence for its Chemor plant, valid from March 6, 2017.
The licence for its Chemor plant also has to be renewed three months prior to the expiry date on Dec 31, 2017.
Trading in Hovid’s securities was halted for an hour yesterday, from 10.56am until 11.56am.
Hovid closed 1.4% higher at 36.5 sen.
A total of 16.47 million shares changed hands.
Did you find this article insightful?